Brain-derived neurotrophic factor as a potential biomarker of cognitive recovery in schizophrenia

doi:10.5498/wjp.v3.i4.93

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5499)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

384

WORD

276

HTML

2462

Figures (1-1)

213

Sum=3335

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

933

Download

1231

Sum=2164

Dec 22, 2013 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Psychiatr. Dec 22, 2013; 3(4): 93-102
Published online Dec 22, 2013. doi: 10.5498/wjp.v3.i4.93

Brain-derived neurotrophic factor as a potential biomarker of cognitive recovery in schizophrenia

Rafael Penadés, Rosa Catalán, Irene López-Vílchez, Bárbara Arias, Alexandre González-Rodríguez, Ana M Galán, Cristóbal Gastó

Rafael Penadés, Rosa Catalán, Alexandre González-Rodríguez, Cristóbal Gastó, Psychiatry and Psychology, Clinical Institute of Neurosciences (ICN), Hospital Clínic, 08036 Barcelona, Spain

Rafael Penadés, Rosa Catalán, Cristóbal Gastó, Department of Psychiatry and Psychobiology, University of Barcelona, 08036 Barcelona, Spain

Rafael Penadés, Rosa Catalán, Irene López-Vílchez, Ana M Galán, Cristóbal Gastó, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain

Rafael Penadés, Rosa Catalán, Bárbara Arias, Cristóbal Gastó, Centro Investigación en Red Salud Mental (CIBERSAM), 28007 Madrid, Spain

Irene López-Vílchez, Ana M Galán, Hemotherapy and Hemostasis, Centre for Biomedical Diagnosis, Hospital Clínic, 08036 Barcelona, Spain

Bárbara Arias, Department of Anthropology, Faculty of Biology and Biomedicine Institute, University of Barcelona, 08036 Barcelona, Spain

Author contributions: All authors equally contributed to write the draft and to revise it critically for the intellectual content; all authors gave their approval of the final version.

Supported by The grants from the Instituto de Salud Carlos III of FIS (PI 11/01958); and the Intramural Grant from CIBERSAM to Penadés R

Correspondence to: Dr. Rafael Penadés, PhD, Psychiatry and Psychology, Clinical Institute of Neurosciences (ICN), Hospital Clínic, C/ Villarroel 170, 08036 Barcelona, Spain. rpenades@clinic.ub.es

Telephone: +34-93-2275400 Fax: +34-93-4035294

Received: June 28, 2013
Revised: October 6, 2013
Accepted: November 1, 2013
Published online: December 22, 2013

Core Tip

Core tip: The lack of diagnostic and treatment markers is one of the most important problems in clinical practice. Brain-derived neurotrophic factor (BDNF) has been proposed as a biomarker of schizophrenia and, more specifically, as a biomarker of cognitive recovery. Evidence collected in this review indicates that there is evidence suggesting that serum BDNF levels are involved in some synaptic plasticity processes. Additionally, serum BDNF levels significantly increased in schizophrenia subjects after neuroplasticity-based cognitive training. All in all, the current consideration of BDNF as a biomarker of cognitive recovery in schizophrenia is promising but still premature.